Director/PDMR Shareholding
Updated : 11:32
07 March 2019
Kainos Group plc
("Kainos" or the "Company")
Director/PDMR Shareholdings
The Company has been notified that on 06 March 2019, Dr John Lillywhite, Chairman, transferred 40,000 ordinary shares in the Company, to a Charitable Incorporated Organisation (CIO), for nil consideration.
The Lillywhite Family Trust (Charity number: 1181785) has been established to promote and advance exclusively charitable purposes, namely the provision of funding for bursaries and scholarships for disadvantaged young people.
Following this notification, Dr Lillywhite holds 460,000 ordinary shares in the Company, representing approximately 0.38% of the total issued shares in the Company.
This announcement is made in accordance with the requirements of the EU Market Abuse Regulation.
The notification of dealing form is set out below:
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a. | Name | Dr John Lillywhite | ||||
2. | Reason for the notification | |||||
a. | Position/status | Chairman/Director | ||||
b. | Initial notification /Amendment | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a. | Name | Kainos Group plc | ||||
b. | LEI | 213800H2PQMIF3OVZY47 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a. | Description of the Financial instrument/ type of instrument Identification code | Ordinary Shares of £0.005 each
ISIN: GB00BZ0D6727 | ||||
b. | Nature of the transaction | Transfer of Ordinary Shares of £0.005 each to the Lillywhite Family Trust for nil consideration. The Lillywhite Family Trust is a Charitable Incorporated Organisation (CIO), Charity Number: 1181785. | ||||
c. | Price(s) and volume(s) |
| ||||
d. | Aggregated information · Aggregated volume · Price |
N/A | ||||
e. | Date of the transaction | 06-03-2019 | ||||
f. | Place of the transaction | Outside of a trading venue | ||||
Ends
For further information, please contact:
Kainos via FTI Consulting LLP
Brendan Mooney, Chief Executive Officer
Richard McCann, Chief Financial Officer
Investec Bank plc +44 20 7597 5970
Patrick Robb / Sebastian Lawrence
Canaccord Genuity +44 20 7523 4606
Simon Bridges / Emma Gabriel
FTI Consulting LLP +44 20 3727 1000
Matt Dixon / Harry Staight
About Kainos
Kainos Group plc is a UK-based provider of Digital Services and Digital Platforms.
The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday Inc. ('Workday') responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise and, now, government customers.
The Group's Digital Platforms comprise specialised digital products in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records ('EMR') is the market leading product for the digitisation of patient notes in the Acute sector of the NHS; and Evolve Integrated Care ('IC') is a SaaS-based integrated care platform for the NHS and international healthcare providers.
Kainos has over 1,300 people across eleven offices in Europe and the USA, working interchangeably across its Services and Platforms divisions.
Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit www.kainos.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.